302440.KS
SK bioscience Co.,Ltd.
KSEKRWEQUITY
Healthcare
DELAYED
Last price
36,500.00
▼ 1,250.00 (3.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
36,800.00
Prev close
37,750.00
Day high
37,000.00
Day low
35,750.00
Volume
73.77K
Market cap
$2.86T
P/E (TTM)
—
52W range
31,800.00 – 61,300.00
Day trading desk
Gap from prior close
-2.52%
Prior close 37,750.00
VWAP
36,255.18
+0.68% from price
Relative volume
0.63×
Normal
Session range
3.50%
35,750.00 – 37,000.00
Position in range
60%
Mid range
ATR (14D)
1,592.86
4.36% of price
Prior day high
39,150.00
PDH
Prior day low
37,100.00
PDL
Bid / ask spread
—
Quote not published
Session volume
73.89K
Avg 117.38K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.95%
+0.4%
1M
+11.45%
+7.7%
3M
-9.20%
-12.3%
6M
-28.01%
-39.1%
YTD
-24.27%
-36.6%
1Y
-20.48%
-40.5%
3Y
-51.01%
-125.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 302440.KS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
53.91M
Total on file
Fundamentals
Market cap$2.86T
Enterprise value$2.76T
Revenue (TTM)$665.42B
Gross profit$63.79B
EBITDA$-57.64B
Net income$-83.29B
EPS (TTM)—
Free cash flow$-315.00B
Total cash$890.16B
Total debt$538.00B
Book value / share—
Shares outstanding78.46M
Float25.96M
Short % of float—
Dividend yield—
Beta (5Y)0.95
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.15
EV / EBITDA-47.96
Gross margin9.59%
Operating margin-26.41%
Profit margin-12.52%
Return on equity-4.34%
Return on assets-3.24%
Debt / equity26.59
Current ratio4.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $651.37B | $267.55B | $369.51B | $456.73B | +143.5% |
| Operating revenue | $651.37B | $267.55B | $369.51B | $456.73B | +143.5% |
| Cost of revenue | $575.44B | $236.57B | $227.26B | $217.11B | +143.2% |
| Gross profit | $75.92B | $30.98B | $142.24B | $239.61B | +145.1% |
| Research & development | $69.86B | $71.35B | $85.74B | $57.96B | -2.1% |
| Selling, general & admin | $48.22B | $40.90B | $25.35B | $27.32B | +17.9% |
| Total operating expense | $199.43B | $169.41B | $154.23B | $124.60B | +17.7% |
| Operating income | -$123.50B | -$138.43B | -$11.99B | $115.01B | +10.8% |
| Net interest income | $6.27B | $3.29B | $12.16B | $2.39B | +90.5% |
| Pre-tax income | -$85.86B | -$89.11B | $7.33B | $141.73B | +3.6% |
| Tax provision | -$29.69B | -$38.99B | -$14.99B | $19.28B | +23.9% |
| Net income | -$57.42B | -$53.88B | $22.32B | $122.45B | -6.6% |
| Net income to common | -$57.42B | -$53.88B | $22.32B | $122.45B | -6.6% |
| Basic EPS | -733.00 | -698.00 | 291.00 | 1,596.00 | -5.0% |
| Diluted EPS | -733.00 | -698.00 | 290.00 | 1,590.00 | -5.0% |
| EBIT | -$76.46B | -$85.42B | $8.73B | $144.19B | +10.5% |
| EBITDA | $14.55B | -$36.20B | $43.49B | $171.43B | +140.2% |
| Basic shares | 78.34M | 77.19M | 76.69M | 76.72M | +1.5% |
| Diluted shares | 78.34M | 77.19M | 76.96M | 77.01M | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $105.55B | $312.70B | $127.03B | $225.29B | — | -66.2% |
| Cash & short-term investments | $906.30B | $1.16T | $1.27T | $1.48T | — | -21.7% |
| Accounts receivable | $122.01B | $94.46B | $12.93B | $39.58B | — | +29.2% |
| Inventory | $189.20B | $211.13B | $80.65B | $187.41B | — | -10.4% |
| Total current assets | $1.25T | $1.58T | $1.38T | $1.78T | — | -21.0% |
| Property, plant & equipment | $1.13T | $982.61B | $315.92B | $293.06B | — | +15.0% |
| Goodwill & intangibles | $193.96B | $124.55B | $22.46B | $18.18B | — | +55.7% |
| Total assets | $2.96T | $2.84T | $1.85T | $2.14T | — | +3.9% |
| Total current liabilities | $326.24B | $310.59B | $135.62B | $380.04B | — | +5.0% |
| Current debt | $0 | $0 | $0 | $83.56B | — | — |
| Long-term debt | $464.74B | $383.33B | — | — | $35.50B | +21.2% |
| Total debt | $469.99B | $392.81B | $20.57B | $113.34B | — | +19.6% |
| Total liabilities | $918.29B | $821.14B | $148.58B | $400.23B | — | +11.8% |
| Retained earnings | $445.26B | $499.76B | $549.42B | $533.38B | — | -10.9% |
| Shareholder equity | $1.79T | $1.80T | $1.70T | $1.74T | — | -0.8% |
| Working capital | $919.89B | $1.27T | $1.25T | $1.40T | — | -27.3% |
| Net tangible assets | $1.59T | $1.68T | $1.68T | $1.72T | — | -5.0% |
| Shares issued | 78.43M | 78.35M | 76.83M | 76.78M | — | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$56.17B | -$50.12B | $22.32B | $122.45B | -12.1% |
| Depreciation & amortisation | $91.02B | $49.23B | $34.76B | $27.24B | +84.9% |
| Change in working capital | $124.75B | $40.06B | -$18.39B | -$208.38B | +211.4% |
| Operating cash flow | $102.51B | -$128.02B | $29.35B | -$124.96B | +180.1% |
| Capital expenditure | -$260.38B | -$172.22B | -$50.30B | -$76.49B | -51.2% |
| Investing cash flow | -$361.76B | $53.56B | -$45.28B | $272.65B | -775.4% |
| Financing cash flow | $41.60B | $252.48B | -$89.58B | -$19.87B | -83.5% |
| Free cash flow | -$157.87B | -$300.24B | -$20.95B | -$201.45B | +47.4% |
| End cash position | $105.55B | $312.70B | $127.03B | $225.29B | -66.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $168.61B | $184.19B | $150.76B | $161.86B | $154.56B | -8.5% |
| Operating revenue | $168.61B | $184.19B | $150.76B | $161.86B | $154.56B | -8.5% |
| Cost of revenue | $153.75B | $179.22B | $117.83B | $149.96B | $128.42B | -14.2% |
| Gross profit | $14.86B | $4.96B | $32.93B | $11.90B | $26.13B | +199.4% |
| Research & development | $20.98B | $17.75B | $19.88B | $20.24B | $12.00B | +18.2% |
| Selling, general & admin | $14.68B | $15.33B | $12.39B | $10.19B | $9.35B | -4.2% |
| Total operating expense | $59.39B | $56.57B | $52.30B | $49.29B | $41.26B | +5.0% |
| Operating income | -$44.54B | -$51.61B | -$19.37B | -$37.40B | -$15.13B | +13.7% |
| Net interest income | $1.15B | $4.77B | $84.41M | $859.12M | $558.14M | -75.9% |
| Pre-tax income | -$47.85B | -$21.32B | -$15.58B | -$35.16B | -$13.80B | -124.5% |
| Tax provision | -$11.68B | $35.09B | -$36.66B | -$18.38B | -$9.73B | -133.3% |
| Net income | -$33.33B | -$57.96B | $24.48B | -$16.48B | -$7.47B | +42.5% |
| Net income to common | -$33.33B | -$57.96B | $24.48B | -$16.48B | -$7.47B | +42.5% |
| Basic EPS | -425.00 | — | 313.00 | -210.00 | -95.00 | — |
| Diluted EPS | -425.00 | — | 313.00 | -210.00 | -95.00 | — |
| EBIT | -$44.12B | -$19.28B | -$12.91B | -$32.89B | -$11.38B | -128.8% |
| EBITDA | -$18.69B | $6.43B | $9.70B | -$11.36B | $9.79B | -390.8% |
| Basic shares | 78.44M | — | 78.21M | 78.36M | 78.59M | — |
| Diluted shares | 78.44M | — | 78.21M | 78.36M | 78.59M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $86.72B | $105.55B | $159.52B | $242.84B | $305.74B | — | -17.8% |
| Cash & short-term investments | $890.16B | $906.30B | $1.01T | $1.10T | $1.18T | — | -1.8% |
| Accounts receivable | $143.18B | $122.01B | $113.72B | $114.67B | $111.33B | — | +17.3% |
| Inventory | $188.70B | $189.20B | $221.99B | $196.62B | $216.78B | — | -0.3% |
| Total current assets | $1.25T | $1.25T | $1.37T | $1.44T | $1.55T | — | +0.6% |
| Property, plant & equipment | $1.14T | $1.13T | $1.11T | $1.08T | $1.04T | — | +1.3% |
| Goodwill & intangibles | $223.43B | $193.96B | $175.20B | $148.08B | $135.36B | — | +15.2% |
| Total assets | $2.99T | $2.96T | $2.92T | $2.85T | $2.90T | — | +1.2% |
| Total current liabilities | $310.28B | $326.24B | $321.99B | $320.39B | $347.57B | — | -4.9% |
| Current debt | — | $0 | $0 | $0 | $0 | $0 | — |
| Long-term debt | $534.21B | $464.74B | $406.45B | $395.94B | $395.11B | — | +14.9% |
| Total debt | $538.00B | $469.99B | $411.13B | $402.11B | $403.18B | — | +14.5% |
| Total liabilities | $968.28B | $918.29B | $847.96B | $829.76B | $861.71B | — | +5.4% |
| Retained earnings | $411.93B | $445.26B | $500.29B | $475.82B | $492.29B | — | -7.5% |
| Shareholder equity | $1.77T | $1.79T | $1.83T | $1.79T | $1.81T | — | -1.0% |
| Working capital | $943.61B | $919.89B | $1.05T | $1.12T | $1.20T | — | +2.6% |
| Net tangible assets | $1.55T | $1.59T | $1.66T | $1.64T | $1.67T | — | -3.0% |
| Shares issued | 78.46M | 78.43M | 78.37M | 78.37M | 78.35M | — | +0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$36.16B | -$56.41B | $21.08B | -$16.78B | -$4.07B | +35.9% |
| Depreciation & amortisation | $25.43B | $25.70B | $22.62B | $21.52B | $21.17B | -1.1% |
| Stock-based compensation | $135.28M | — | — | — | — | — |
| Change in working capital | -$23.46B | $46.76B | $11.97B | -$16.78B | $82.80B | -150.2% |
| Operating cash flow | -$42.53B | $23.66B | $20.65B | -$4.55B | $62.75B | -279.7% |
| Capital expenditure | -$67.26B | -$58.44B | -$70.94B | -$81.53B | -$49.47B | -15.1% |
| Investing cash flow | -$37.81B | -$128.66B | -$105.24B | -$52.56B | -$75.30B | +70.6% |
| Financing cash flow | $58.06B | $46.91B | -$1.82B | -$1.65B | -$1.84B | +23.8% |
| Free cash flow | -$109.80B | -$34.77B | -$50.29B | -$86.09B | $13.27B | -215.7% |
| End cash position | $86.72B | $105.55B | $159.52B | $242.84B | $305.74B | -17.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -340.68 | -229.00 | +32.8% |
| Dec 2025 | -688.96 | -740.00 | -7.4% |
| Sep 2025 | -597.04 | 313.00 | +152.4% |
| Jun 2025 | -199.73 | -210.00 | -5.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -340.68 | 1 | $178.90B | +18.7% |
| Next quarter | 218.62 | 1 | $188.10B | +2.1% |
| Current year | -1,323.04 | 1 | $687.50B | +5.6% |
| Next year | -966.62 | 3 | $753.46B | +267.7% |
Analyst targets & ownership
Mean target$32,500.00
High target$46,000.00
Low target$25,000.00
Implied upside-10.96%
Analyst count4
ConsensusUNDERPERFORM
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell2 / 1
Held by insiders68.71%
Held by institutions3.31%
Institutions holding69
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
36,915.00
-1.12% from price
SMA 20
35,550.00
+2.67% from price
SMA 50
36,343.00
+0.43% from price
SMA 100
39,184.50
-6.85% from price
SMA 200
44,470.50
-17.92% from price
EMA 12
36,415.74
+0.23% from price
EMA 26
36,114.05
+1.07% from price
EMA 50
36,820.38
-0.87% from price
RSI (14)
51.7
Neutral
MACD (12,26,9)
301.69
Hist 242.41
ATR (14)
1,592.86
4.36% of price
Realised vol 30D
41.5%
Annualised
Bollinger upper
38,670.74
20, 2σ
Bollinger lower
32,429.26
20, 2σ
50 / 200 cross
Death
36,343.00 vs 44,470.50
Trend bias
Below 200
-17.92%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.36
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
41.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-45.9%
Peak to trough
Max drawdown 5Y
-90.3%
Peak to trough
ATR 14
1,592.86
4.36% of price
Beta (reported)
0.95
5Y monthly, from filing
Headlines
What Happens When Social Security Takes Your Benefits Because You Work Too Much?
Motley Fool · 9m ago
Carney warned about economic coercion. Now Trump is testing the Canadian prime minister
Associated Press · 17m ago
Alibaba Launches Record $10 Billion Share Sale to Enter the AI Race
BeInCrypto · 20m ago
Pershing Square (PS) Following Earnings Loss And New Venture Launch Faces A Valuation Test
Simply Wall St. · 21m ago
Tenet Healthcare (THC) Stock May Be 49% Undervalued After Raised Outlook
Simply Wall St. · 21m ago
Morgan Housel warns of a looming career threat for your child
TheStreet · 22m ago
History Says You Should Know These 3 Things Before Buying the Vanguard S&P 500 ETF (VOO)
Motley Fool · 24m ago
He Camped One Weekend on Riverfront Land Inside His IRA. Medicare Charged Him for It Two Years Later.
24/7 Wall St. · 26m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.